ESTEVE PHARMACEUTICALS S.A.
ESTEVE is a privately owned international specialty pharmaceutical company with pharmaceutical operations and a contract development and manufacturing business.
Last updated September 25, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
ESTEVE is an international specialty pharmaceutical company whose stated purpose is to improve people’s lives. The company says its work is guided by a patient-centred approach to unmet medical needs, with a focus on innovative and environmentally sustainable solutions. It identifies people, transparency, and accountability as core values. Its pharmaceutical business has affiliates in Spain, Germany, France, the United Kingdom, Portugal, Italy, Austria, and the United States. The company says these affiliates facilitate collaboration and distribution of its specialty products. The supplied sources do not identify specific marketed medicines or therapeutic areas, so individual products cannot be reliably named here. Alongside Pharma, ESTEVE operates a contract development and manufacturing business, referred to in recent company news as ESTEVE CDMO. Its industrial sites in Spain, Mexico, and China develop and manufacture active pharmaceutical ingredients for third parties. The company describes its CDMO activities as specializing in small-molecule active pharmaceutical ingredients and pharmaceutical intermediates. ESTEVE describes itself as privately owned. The governance page identifies Albert Esteve as chairman of the board and Staffan Schüberg as chief executive officer. Its history page links the company’s origins and continuing entrepreneurial legacy to Dr. Antoni Esteve i Subirana and describes its journey as spanning nearly a century; the supplied evidence does not give an exact founding year or headquarters address.
History
ESTEVE presents its history as a pharmaceutical enterprise shaped by the aspiration to improve people’s lives. Its official history page associates the company’s founding legacy with Dr. Antoni Esteve i Subirana, describing his creative, innovative, and entrepreneurial spirit as continuing to influence the company. The page characterizes the company’s journey as nearly a century long, but the supplied material does not state a precise founding date. The company’s current identity combines an international specialty pharmaceutical business with industrial activities serving third parties. Its Pharma affiliates are based in Spain, Germany, France, the United Kingdom, Portugal, Italy, Austria, and the United States, supporting collaboration and distribution of specialty products. ESTEVE also reports industrial sites in Spain, Mexico, and China where it develops and manufactures active pharmaceutical ingredients for other companies. In its present-day corporate description, ESTEVE places patients at the centre of efforts to address unmet medical needs and emphasizes innovation and environmental sustainability. It also identifies people, transparency, and accountability as guiding values. The group’s contract development and manufacturing operation is presented as ESTEVE CDMO and focuses on small-molecule APIs and pharmaceutical intermediates. Company announcements in 2026 describe expansion activity in the United States and Spain and the introduction of a new CDMO brand identity. ESTEVE’s governance disclosure describes it as a privately owned international pharmaceutical company. It identifies Albert Esteve as chairman of the board and Staffan Schüberg as chief executive officer. The supplied sources do not provide a precise founding year, headquarters address, detailed sequence of historical milestones, or a list of named medicines; these details are therefore not stated here.
Company origins associated with Dr. Antoni Esteve i Subirana
Chicago small-molecule API facility expansion commences
CDMO brand identity and Girona capacity plans announced
Company highlights international expansion and B Corp Certification
Products and positioning
A privately owned international specialty pharmaceutical company with a patient-centred Pharma business and a CDMO operation focused on small-molecule APIs and pharmaceutical intermediates.
Specialty pharmaceutical products
The company says its pharmaceutical affiliates facilitate collaboration and distribution of its specialty products; the supplied sources do not name individual medicines.
Active pharmaceutical ingredients and pharmaceutical intermediates
ESTEVE’s industrial sites develop and manufacture active pharmaceutical ingredients for third parties; its CDMO business also identifies pharmaceutical intermediates as a focus.
Pharma CDMO services
The company presents ESTEVE CDMO as a contract development and manufacturing business specializing in small-molecule APIs and advanced pharmaceutical intermediates.
Brand decisions
- Plan additional spray dryers and containment at CelràOther
- Expand the Chicago small-molecule API facilityOther
Recent events
ESTEVE agrees to acquire Riemser[5]
Reported:
ESTEVE announced an agreement to acquire all shares of German pharmaceutical company Riemser from Ardian. The acquisition was expected to be completed within Q1 2020.
ESTEVE announces agreement to acquire RIEMSER[6]
Reported:
ESTEVE announced an agreement to acquire 100% of the shares in specialty pharmaceutical company RIEMSER from Ardian.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/esteve-pharmaceuticals-sa · Editorial policy · How profiles are compiled